Skip to main content

EDITORIAL article

Front. Genet.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1470698
This article is part of the Research Topic Utilization of Pharmacogenomics in Clinical Practice View all 10 articles

Editorial: Utilization of Pharmacogenomics in Clinical Practice

Provisionally accepted
  • 1 Oncology R&D, Department of Oncology, Astrazeneca, Boston, Massachusetts, United States
  • 2 Department of Medical Sciences, University of Turin, Turin, Piedmont, Italy
  • 3 Phytoveda Pvt. Ltd, Mumbai, Maharashtra, India
  • 4 Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, Virginia, United States
  • 5 Australian Centre for Precision Health, University of South Australia, Adelaide, Australia

The final, formatted version of the article will be published soon.

    Keywords: Pharmacogenomic (PGx) research, clinical practice, Genomic education, Pharmacology, Adverse drug (event), Drug efficacy and safety

    Received: 25 Jul 2024; Accepted: 31 Jul 2024.

    Copyright: © 2024 Papachristos, Cusato, Nair, Maggo and Suppiah. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Vijayaprakash Suppiah, Australian Centre for Precision Health, University of South Australia, Adelaide, Australia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.